vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and Hilltop Holdings Inc. (HTH). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $300.5M, roughly 1.1× Hilltop Holdings Inc.). HAEMONETICS CORP runs the higher net margin — 13.2% vs 13.0%, a 0.2% gap on every dollar of revenue. Over the past eight quarters, Hilltop Holdings Inc.'s revenue compounded faster (0.6% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Hilltop Holdings Inc. is a financial holding company based in Dallas, Texas. It offers financial products and banking services through three primary subsidiaries: PlainsCapital Bank, PrimeLending, and HilltopSecurities.
HAE vs HTH — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $300.5M |
| Net Profit | $44.7M | $39.0M |
| Gross Margin | 59.7% | — |
| Operating Margin | 19.9% | — |
| Net Margin | 13.2% | 13.0% |
| Revenue YoY | -2.7% | — |
| Net Profit YoY | 19.3% | -12.4% |
| EPS (diluted) | $0.95 | $0.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $300.5M | ||
| Q4 25 | $339.0M | $329.9M | ||
| Q3 25 | $327.3M | $330.2M | ||
| Q2 25 | $321.4M | $303.3M | ||
| Q1 25 | $330.6M | $318.5M | ||
| Q4 24 | $348.5M | $301.1M | ||
| Q3 24 | $345.5M | $305.5M | ||
| Q2 24 | $336.2M | $297.0M |
| Q1 26 | — | $39.0M | ||
| Q4 25 | $44.7M | $41.6M | ||
| Q3 25 | $38.7M | $45.8M | ||
| Q2 25 | $34.0M | $36.1M | ||
| Q1 25 | $58.0M | $42.1M | ||
| Q4 24 | $37.5M | $35.5M | ||
| Q3 24 | $33.8M | $29.7M | ||
| Q2 24 | $38.4M | $20.3M |
| Q1 26 | — | — | ||
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 19.9% | 16.1% | ||
| Q3 25 | 17.9% | 18.4% | ||
| Q2 25 | 16.8% | 16.3% | ||
| Q1 25 | 21.6% | 18.1% | ||
| Q4 24 | 16.9% | 14.7% | ||
| Q3 24 | 15.0% | 13.9% | ||
| Q2 24 | 11.8% | 10.0% |
| Q1 26 | — | 13.0% | ||
| Q4 25 | 13.2% | 12.6% | ||
| Q3 25 | 11.8% | 13.9% | ||
| Q2 25 | 10.6% | 11.9% | ||
| Q1 25 | 17.5% | 13.2% | ||
| Q4 24 | 10.8% | 11.8% | ||
| Q3 24 | 9.8% | 9.7% | ||
| Q2 24 | 11.4% | 6.8% |
| Q1 26 | — | $0.64 | ||
| Q4 25 | $0.95 | $0.68 | ||
| Q3 25 | $0.81 | $0.74 | ||
| Q2 25 | $0.70 | $0.57 | ||
| Q1 25 | $1.17 | $0.65 | ||
| Q4 24 | $0.74 | $0.55 | ||
| Q3 24 | $0.66 | $0.46 | ||
| Q2 24 | $0.74 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | — |
| Total DebtLower is stronger | $1.2B | $990.8M |
| Stockholders' EquityBook value | $911.5M | $2.2B |
| Total Assets | $2.5B | $15.7B |
| Debt / EquityLower = less leverage | 1.34× | 0.46× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $363.4M | — | ||
| Q3 25 | $296.4M | — | ||
| Q2 25 | $292.9M | — | ||
| Q1 25 | $306.8M | — | ||
| Q4 24 | $320.8M | — | ||
| Q3 24 | $299.3M | — | ||
| Q2 24 | $344.4M | — |
| Q1 26 | — | $990.8M | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $2.2B | ||
| Q4 25 | $911.5M | $2.2B | ||
| Q3 25 | $849.2M | $2.2B | ||
| Q2 25 | $882.3M | $2.2B | ||
| Q1 25 | $820.8M | $2.2B | ||
| Q4 24 | $906.9M | $2.2B | ||
| Q3 24 | $878.9M | $2.2B | ||
| Q2 24 | $905.4M | $2.1B |
| Q1 26 | — | $15.7B | ||
| Q4 25 | $2.5B | $15.8B | ||
| Q3 25 | $2.4B | $15.6B | ||
| Q2 25 | $2.5B | $15.4B | ||
| Q1 25 | $2.5B | $15.8B | ||
| Q4 24 | $2.5B | $16.3B | ||
| Q3 24 | $2.5B | $15.9B | ||
| Q2 24 | $2.5B | $15.6B |
| Q1 26 | — | 0.46× | ||
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | — |
| Free Cash FlowOCF − Capex | $87.2M | — |
| FCF MarginFCF / Revenue | 25.7% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | 2.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $93.6M | $-38.7M | ||
| Q3 25 | $111.3M | $273.0M | ||
| Q2 25 | $17.4M | $-234.6M | ||
| Q1 25 | $116.6M | $5.8M | ||
| Q4 24 | $43.8M | $273.9M | ||
| Q3 24 | $48.8M | $515.6M | ||
| Q2 24 | $-27.4M | $-435.3M |
| Q1 26 | — | — | ||
| Q4 25 | $87.2M | $-55.5M | ||
| Q3 25 | $106.3M | $271.0M | ||
| Q2 25 | $13.6M | $-234.6M | ||
| Q1 25 | $100.9M | $5.0M | ||
| Q4 24 | $35.2M | $266.8M | ||
| Q3 24 | $39.4M | $513.8M | ||
| Q2 24 | $-33.1M | $-437.3M |
| Q1 26 | — | — | ||
| Q4 25 | 25.7% | -16.8% | ||
| Q3 25 | 32.5% | 82.1% | ||
| Q2 25 | 4.2% | -77.4% | ||
| Q1 25 | 30.5% | 1.6% | ||
| Q4 24 | 10.1% | 88.6% | ||
| Q3 24 | 11.4% | 168.2% | ||
| Q2 24 | -9.8% | -147.2% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 5.1% | ||
| Q3 25 | 1.5% | 0.6% | ||
| Q2 25 | 1.2% | 0.0% | ||
| Q1 25 | 4.7% | 0.3% | ||
| Q4 24 | 2.5% | 2.4% | ||
| Q3 24 | 2.7% | 0.6% | ||
| Q2 24 | 1.7% | 0.7% |
| Q1 26 | — | — | ||
| Q4 25 | 2.09× | -0.93× | ||
| Q3 25 | 2.88× | 5.96× | ||
| Q2 25 | 0.51× | -6.50× | ||
| Q1 25 | 2.01× | 0.14× | ||
| Q4 24 | 1.17× | 7.71× | ||
| Q3 24 | 1.44× | 17.36× | ||
| Q2 24 | -0.71× | -21.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
HTH
| Noninterest Income | $188.4M | 63% |
| Net Interest Income | $112.1M | 37% |
